Healthcare provider profile · identity verified

John Thomas Matera, MD

Allopathic & Osteopathic Physicians|Hospitalist · BLUE ISLAND, IL · NPI 1770970931

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show John Thomas Matera, MD received $45.00 in general payments during 2025 across 1 reported records.

Lilly USA, LLC accounted for 100.0% of that reported general-payment amount.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Jardiance by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Trulicity by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$45.00

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Lilly USA, LLC	Unresolved — no canonical attribution shown	$45.00	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Education	$45.00	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Payment records were found, but the reported records did not identify a specific associated product for this analysis.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	108	33
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	MOUNJARO open payments reported associated product	CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455	Mounjaro · 2024 Exact normalized brand match · 1 Part D row	41	suppressed by CMS
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	TRULICITY open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601	Trulicity · 2024 Exact normalized brand match · 1 Part D row	92	25

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1092	336
Amlodipine Besylate	Amlodipine Besylate	712	242
Metformin Hcl	Metformin Hcl	464	148
Losartan Potassium	Losartan Potassium	453	134
Gabapentin	Gabapentin	391	127
Albuterol Sulfate Hfa	Albuterol Sulfate	377	137
Lisinopril	Lisinopril	358	105
Hydrochlorothiazide	Hydrochlorothiazide	290	97
Metoprolol Succinate	Metoprolol Succinate	252	82
Furosemide	Furosemide	234	75
Omeprazole	Omeprazole	223	65
Pantoprazole Sodium	Pantoprazole Sodium	209	59
Levothyroxine Sodium	Levothyroxine Sodium	189	51
Tamsulosin Hcl	Tamsulosin Hcl	178	68
Rosuvastatin Calcium	Rosuvastatin Calcium	175	61
Famotidine	Famotidine	174	55
Glipizide	Glipizide	168	59
Carvedilol	Carvedilol	150	54
Metoprolol Tartrate	Metoprolol Tartrate	150	52
Eliquis	Apixaban	134	39
Nifedipine Er	Nifedipine	129	37
Sertraline Hcl	Sertraline Hcl	125	39
Fluticasone Propionate	Fluticasone Propionate	122	69
Simvastatin	Simvastatin	121	43
Enalapril Maleate	Enalapril Maleate	115	43
Montelukast Sodium	Montelukast Sodium	111	35
Allopurinol	Allopurinol	108	32
Jardiance	Empagliflozin	108	33
Trazodone Hcl	Trazodone Hcl	108	27
Potassium Chloride	Potassium Chloride	107	36
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	101	22
Pravastatin Sodium	Pravastatin Sodium	99	31
Tramadol Hcl	Tramadol Hcl	97	33
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	93	31
Duloxetine Hcl	Duloxetine Hcl	92	23
Trulicity	Dulaglutide	92	25
Alendronate Sodium	Alendronate Sodium	81	28
Donepezil Hcl	Donepezil Hcl	80	23
Clopidogrel	Clopidogrel Bisulfate	79	31
Ozempic	Semaglutide	79	26
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	75	21
Metformin Hcl Er	Metformin Hcl	74	28
Finasteride	Finasteride	70	19
Hydralazine Hcl	Hydralazine Hcl	64	24
Escitalopram Oxalate	Escitalopram Oxalate	62	15
Quetiapine Fumarate	Quetiapine Fumarate	61	14
Symbicort	Budesonide/Formoterol Fumarate	61	19
Spironolactone	Spironolactone	57	23
Oxybutynin Chloride Er	Oxybutynin Chloride	55	17
Glimepiride	Glimepiride	54	15
Clonidine Hcl	Clonidine Hcl	53	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	53	23
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	52	27
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	51	20
Mirtazapine	Mirtazapine	51	20
Levetiracetam	Levetiracetam	49	13
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	45	16
Amitriptyline Hcl	Amitriptyline Hcl	44	suppressed
Ibuprofen	Ibuprofen	43	26
Januvia	Sitagliptin Phosphate	42	15
Prednisone	Prednisone	42	29
Sildenafil Citrate	Sildenafil Citrate	42	13
Chlorthalidone	Chlorthalidone	41	12
Mounjaro	Tirzepatide	41	suppressed
Paroxetine Hcl	Paroxetine Hcl	39	suppressed
Atenolol	Atenolol	37	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	36	13
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	36	19
Meclizine Hcl	Meclizine Hcl	35	11
Citalopram Hbr	Citalopram Hydrobromide	34	suppressed
Breo Ellipta	Fluticasone/Vilanterol	33	suppressed
Diclofenac Sodium	Diclofenac Sodium	32	16
Lovastatin	Lovastatin	31	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	30	18
Fenofibrate	Fenofibrate	28	suppressed
Glipizide Er	Glipizide	28	12
Hydrocortisone	Hydrocortisone	27	19
Spiriva Handihaler	Tiotropium Bromide	27	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	27	suppressed
Propranolol Hcl	Propranolol Hcl	26	suppressed
Ventolin Hfa	Albuterol Sulfate	26	suppressed
Entresto	Sacubitril/Valsartan	25	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	25	18
Humalog Kwikpen U-100	Insulin Lispro	24	suppressed
Valsartan	Valsartan	24	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	23	suppressed
Novolin 70-30	Insulin Nph Hum/Reg Insulin Hm	23	suppressed
Xarelto	Rivaroxaban	23	suppressed
Benazepril Hcl	Benazepril Hcl	22	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	22	suppressed
Ezetimibe	Ezetimibe	21	suppressed
Memantine Hcl	Memantine Hcl	21	suppressed
Novolog Flexpen	Insulin Aspart	21	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	20	suppressed
Warfarin Sodium	Warfarin Sodium	20	suppressed
Alcohol Pads	Alcohol Antiseptic Pads	19	suppressed
Labetalol Hcl	Labetalol Hcl	19	suppressed
Risperidone	Risperidone	19	suppressed
Bumetanide	Bumetanide	18	suppressed
Divalproex Sodium Er	Divalproex Sodium	18	suppressed
Soliqua 100-33	Insulin Glargine/Lixisenatide	18	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	17	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	16	suppressed
Ropinirole Hcl	Ropinirole Hcl	16	suppressed
Colchicine	Colchicine	14	11
Farxiga	Dapagliflozin Propanediol	14	suppressed
Levemir Flexpen	Insulin Detemir	14	suppressed
Loperamide	Loperamide Hcl	14	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	14	suppressed
Single Use Swab	Alcohol Antiseptic Pads	14	11
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	14	13
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Amiloride Hcl	Amiloride Hcl	13	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	13	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	13	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	13	suppressed
Pro Comfort Alcohol Pads	Alcohol Antiseptic Pads	13	suppressed
Torsemide	Torsemide	13	suppressed
Abilify Maintena	Aripiprazole	12	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	12	suppressed
Folic Acid	Folic Acid	12	suppressed
Incruse Ellipta	Umeclidinium Bromide	12	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Methenamine Hippurate	Methenamine Hippurate	12	suppressed
Novolin 70-30 Flexpen	Insulin Nph Hum/Reg Insulin Hm	12	suppressed
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	11	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	11	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	11	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	11	suppressed
Lithium Carbonate Er	Lithium Carbonate	11	suppressed
Nystatin	Nystatin	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$45.00 · 1 records	Lilly USA, LLC	—	3	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error